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Understanding the contributions that the laboratory can make in
product/process development, process improvement, market surveil-
lance and general business is key to the pharmaceutical business
today. Poor laboratory practice yields compliance issues, increased
cost, increased cycle time and delayed product introductions. This
paper covers key areas of customer satisfaction, the role of quality
control and quality assurance laboratories, measures of account-
ability and progress, and an example of how laboratory robotics
can help meet important goals.
Introduction
The objective of this paper is to prompt thought and
discussion on the work of analytical laboratories, and
their contribution and importance to the business.
Firstly, a brief background of Janssen Pharmaceutica is
given to establish a point of comparison to other com-
panies and businesses.
. Janssen Pharmaceutica is the pharmaceutical sector
of Johnson & Johnson.
. It has sales in excess of £ 1.5 billion.
. Its headquarters are in Belgium.
. It produces primarily for USA.
. It competes internally and externally.
Janssen Pharmaceutica is a corporate entity which devel-
ops policies and dictates and monitors ® nancial and
business expectations; the corporate sta￿ provide ® nan-
cial, business and ethics goals. The focus of the company
is stated in its Credo, a document established over 75
years ago by its founder. The Credo clearly documents
the order of priority: customer; employee; community;
and stockholder.
Janssen is unique within J&J in that the franchise head-
quarters are in Belgium, the production facility is in
Gurabo, Puerto Rico, and US administrative and la-
boratory areas are in New Jersey. This is critical to
business success as it mandates recognition and under-
standing of cultural and regulatory di￿ erences. Trans-
lated to the laboratory aspects of the business, Janssen’s
methods and laboratory processes must meet the require-
ments of key global regulatory authorities, yet play out
within the cultural guidelines of the countries supplied.
As one of the J&J family of companies, Janssen is
expected to compete internally and externally for best
practice and benchmark position.
Discussion
Janssen’s Credo:
. We believe our ® rst responsibility is to the doctors,
nurses, patients, to mothers and fathers and to all
others who use our products and services.
. In meeting their needs, everything we do must be of
high quality.
. We must constantly strive to reduce our costs in
order to maintain reasonable prices.
. Customers’ orders must be serviced promptly and
accurately. Our suppliers and distributors must
have an opportunity to make a fair pro® t. . .
As a division of J&J, Janssen’s direction is clear: focus on
the customer! The pharmaceutical industry must recog-
nize that the customer has changed and continues to
change. In the past, the doctors and the fee-for-service
approach were key customers. Today, it is the Managed
Care Organizations, the Federal Government and Phar-
maceutical Business Management Organizations. No
matter how speci® c customers are segmented, they expect
pharmaceutical products to be:
. safe and e￿ cacious;
. compliant with regulations;
. available when requested (no backorder);
. reasonably and competitively priced;
. statistically monitored, producing outcomes data
(for the pharmaceutical business).
This is not new for the pharmaceutical business. How-
ever, another suggestion would be to view the regulatory
agencies that review, approve and monitor processes and
products. These agencies are also key customers as they
can deny approval, signi® cantly a￿ ect business with their
requirements, and impact product availability (recall,
seizure, etc.). Regulatory requirements are as follows:
. management responsibility;
. quality systems established;
. training and competency of personnel;
. documentation;
. data management.
At Janssen, these customer requirements are covered by
three categories: quality, cost and time. These need to be
discussed as they a￿ ect the laboratoriesÐ a critical part of
the business. Customers expect the product to be safe and
e￿ cacious, this is not negotiable! Customer expectations
are addressed as follows.
Product life cycle:
. development;
. launch;
. market surveillance.
During product development, methods are developed to
ensure that the drug is present in the quantity expected
and that it is free from other substances, impurities, etc.
When the product islaunched, each batch istested by the
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http://www.tandf.co.uk/journals/tf/14639246.html 47Quality Control Laboratories to ensure that it meets all
speci® cations. The laboratory results in conjunction with
process evaluation determine the product disposition.
Areas of focus are as follows.
Product disposition:
. Does it meet the required speci® cation? Disso?
Content uniformity? Etc.?
. Is it within the normal range? Is it out of trend?
. Does our documentation support our results?
. Is the product properly protected by its packaging
to ensure its stability throughout its shelf-life?
Quality programs are necessary that support all of these
decisions. The laboratory plays a primary role in deter-
mining the product’s disposition. If the product is tested
incorrectly, it could be a major problem for the patient
and/or company. There is no doubt that the role of the
laboratory in product disposition is a critical one.
Market surveillance:
. stability testing;
. complaint handling;
. adverse events.
Another role the laboratory plays is monitoring the
product during its shelf-life. This is achieved through
stability testing of representative batches throughout
their expiration period. While this may seem simple, it
is not. One must consider global stability requirements,
where the product will be sold, and how the product will
be shipped and stored. It is one thing to ship the product
within the US, it is another to ship it to Zambia or New
Zealand or other parts of the world where the climate
and storage capabilities may be di￿ erent. The product
dispositioned at release must meet all requirements
throughout its shelf-life.
Besides performing stability tests and monitoring all the
processes that accompany that, the labs also evaluate
complaints or adverse event samples that are returned
from the ® eld. While this is not done in all cases, retained
samples are tested and may be the determining factor for
product withdrawal or recall. Again, there should be no
doubt about the role the laboratory plays with respect to
the life cycle of the product, assuring its safety and
compliance to speci® cation.
The laboratory is not only concerned with testing; there
are quality systems that must be built around the testing
programs. The need for these cannot be overemphasized.
Janssen’s quality strategy is depicted in the quality
pyramid shown in ® gure 1.
The ® rst step is to establish quality systems as the
foundation, systems, e.g. complaint handling, validation
(product, process software, etc.). Janssen is now entering
the second phase of automation of systems and data so
that information is readily available and actionable. The
ultimate goal is to reach the pinnacle of the pyramid;
process reliability reduced testing; truly PREVENTIVE
NOT REACTIVE. To monitor the progress in this
journey, quality measures were established.
Quality/key measures:
. number of observations/number of inspections;
. number of signi® cant observations;
. number of warning letters;
. per cent ® rst pass approval for pre-approval inspec-
tions.
The last point listed above is the future of Janssen
Pharmaceutica, new products. Every pre-approval in-
spection that Janssen has had has focused on the labora-
tory, the lab data and process/product/software
validation. Examples of expectations and e￿ orts to
excel in this aspect of meeting the FDA, our customer’s
expectations, are listed as follows.
E￿ orts to improve ® rst pass approval for pre-approval
inspections:
. analytical method technical transfer ® le (AMTTF);
. training of analysts;
. supervisor ratios;
. documentation;
. instrumentation;
. investigations/deviations;
. audits.
From evaluating the issues of past inspections, these were
the main issues that needed improvement. Firstly we deal
with method development (® gure 2).
Training
Reduced
Testing
Systems  Automated
MRB,  Complaints,  Change
Control,  Stability,  Validation,  etc.
Data  Available  on
Demand
$ $
$ $ $ $ $ $
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QUALITY  STRATEGY
Figure 1.
 
 
 
You  never  tell  us  what 
you  want,  we  never  have 
enough time  to do things
well!
You never  give  us  robust,
cost  efficient methods;
they  are  always  developed
  for  running  them once  a
week  instead of twenty
times  a day,  seven  days
a week!
Figure 2.
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48While not everything has been corrected, clear require-
ments have been developed with checkpoints of evalua-
tion by the development laboratory’s key customer, QA/
OPS labs. Together the groups came up with the analy-
tical method technical transfer ® le (AMTTF). Thisliving
document is an assimilation of three documents: a
method development report; a method validation report;
and a method transfer report.
The method development report documents all the per-
tinent information on how the method was developed,
what columns were tested, pH and pressure parameters,
etc. The purpose of this document is to serve those who
follow as a historical perspective on any issues relevant to
this speci® c compound and method. Later in the product
life cycle, if questions arise, the OPS and QA groups can
go back into this document and look for the pertinent
information.
The method validation report documents all the data
that support the key parameters of the method. It con-
tains data con® rming that the method is robust and
meets the requirements of global compendia.
The method transfer report is the formal documentation
that the method has been transferred to the OPS/QA
laboratories. This report contains the overall results and
executive summary, the transfer protocol and the transfer
data supporting that the method can be successfully run
at an alternative laboratory location.
Each of these documents has an SOP supporting the
requirements and who must approve them. This e￿ ort
established the foundation for improving communication
within internal groups, clari® ed the expectations of the
internal customers, and clearly meets the expectations of
external customers, the FDA. As the product line ma-
tures, OPS/QA then work to re® ne the methods as
appropriate to improve e￿ ciencies and reduce cost.
Laboratory training: Laboratory Analytical Training
and Certi® cation Course:
. co-developed by J&J and Drew University;
. two weeks of intense training (classroom and hands-
on) ;
. test results required for certi® cation;
. remediation training;
. future programs.
Simultaneously to developing the AMTTF process,
under the guidance of Hank Avallone, Executive Direc-
tor of Compliance, and Nancy Corkum, COO of IRI,
J&J worked with key lecturers and Drew University to
develop an analytical chemistry Analyst Certi® cation
Program. The Program brings in lecturers to present
compliance and technical information that the analyst
needs to know to work within a compliant pharmaceu-
tical laboratory. The Program spans 2 weeks, and in-
cludes verbal and written tests, and application and
workbook evaluation. The goal is for all analysts to
receive a certi® cation on a periodic basis. For those few
analysts who do not certify, a remediation program has
been developed. Future enhancements to this program
include a program specializing in HPLC technology and
managerial training.
Additionally, there is a need for a strong supervisor/
analyst relationship. Janssen’s current ratio of analysts
to supervisors is 8:1. While this initially seemed costly to
the organization, it has begun to show payback in
attention to addressing instrumentation and general
laboratory issues providing immediate feedback to those
new analysts whoare learning the methods, processes and
expectations. This ratio provides for review of data,
review of training needs, reasonable time for personnel
development and, in general, good laboratory manage-
ment practices. By implementing this approach, it was
discovered that some of the instrumentation in the lab
was not appropriate for the type of work being per-
formed. It was also discovered that training approaches
were not consistent with laboratory practices. These are
the types of issues that go unresolved or unnoticed until
they become a problem if the analyst:supervisor ratio
exceeds 10:1.
Three key areas of laboratory documentation received
attention in the corrective action review:
. training records;
. data review and archival;
. data management.
Analysts had been trained along the lines of laboratory
technology: dissolution, assay, etc. Upon closer scrutiny,
it was discovered that this was not su￿ cient, it was
necessary to ensure that analysts were trained on each
speci® c method and SOP. This provided assurance that
all aspects of testing were understood; there could no
longer be reasons, e.g. `I didn’t know’ or `I wasn’t aware’.
Areas, e.g. safety, methodology and data calculations are
all included in this training.
The data are evaluated by the analyst and then by a peer
reviewer. After passing this process, the data are reviewed
again by the supervisor. Prior to entering the data into
the various reports (stability, process characterization or
validation), it isveri® ed again against the original data to
ensure that typos and transposition errors are minimized.
All data are then ® led for easy retrieval.
Instrumentation also presented itself as an issue. Much of
the instrumentation was outdated and unable to perform
as necessary for some of the more complex methods. This
resulted in a sizeable investment, in excess of $1MM. In
order to maintain a competitive advantage in this area,
new instrumentation is constantly being evaluated for
improvements.
Last, but certainly not least, it was necessary to focus on
the quality and timeliness of investigations. Although
analysts were trained and up-to-date instrumentation
was provided, out-of-speci® cation and out-of-trend re-
sults were still encountered from time to time. Janssen’s
record on addressing investigations adequately and in a
timely manner was poor. It was necessary to refocus and
apply areas of scrutiny by the FDA investigators and,
from a business perspective, inventory levels su￿ ered.
General training programs have been held on how to
write an investigation, the key elements of an investiga-
tion, and the expected timeliness of closure. Although all
the goals have not yet been met, progress is being made.
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addressed, a periodic laboratory audit program was
established, whereby the Compliance Group performs
audits no less than once every 6 months. These audits
are generally unannounced or announced within 2 or 3
days of the audit. This process not only ensures that
attention stays focused, but also prepares the laboratory
personnel for audits from the customer, the FDA. How to
answer questions and how to present data are covered,
the following words are avoided as far as possible:
. contaminated;
. failure;
. violation;
. backorder/cost savings;
. business decision;
. possibly/may/might.
The FDA expects that products, methods and processes
are understood, and that decisions are made based upon
written procedures and science, not on business needs.
They also expect de® nitive answers to out-of-speci® cation
or out-of-trend investigations, are not satisfactory!
Additionally, the Compliance Group performs a pre-PAI
readiness audit to ensure the labs are prepared in the
areas speci® cally associated with the new product await-
ing approval.
From experience at Janssen, these are areas that are
focused on. To remain alert to the FDA, the customer’s
thinking, FDA citations of other non-J&J companies
were investigated. For example:
United States versus Biocraft Laboratories (7/94):
. stability plan;
. failure investigation procedure;
. analyst training;
. adequate methods, facilities and controls;
. adequate methods, equipment, record keeping and
controls at each laboratory.
The FDA guide to inspections of Pharmaceutical Quality
Control Laboratories, issued in July 1993 was reviewed.
This document stressed keeping SOPs current. Current
areas of focus are raw data management, data reproces-
sing and integration, and in-depth review of the CFR. It
is hoped that improvement will continue in meeting the
requirements of internal and external customers, yielding
high-quality product, consistently. In addressing the
compliance aspects, it is expected that con® dence will
be built with the customer, the FDA, such that when they
inspect, their ® ndings are not signi® cant. If a good
compliance pro® le is maintained, the ultimate goal will
be approval of new products without an inspection. The
business impact here is quite signi® cant in time and
dollars (speed to market).
As reported in the Wall Street Journal and the Pink
Sheets, last month, Steris, a division of Shein Pharma-
ceuticals had a very di￿ cult PAI inspection. Government
agents halted production. The stock plunged 39% from
$32 to 14 3
8. It a￿ ected the scheduled launching of 11 of
23 new products. The warrant for the seizure noted
uncorrected problems, e.g.:
. failure to maintain sanitized equipment;
. failure to establish adequate procedures for produc-
tion and laboratory controls;
. failure thoroughly to investigate unexplained discre-
pancies in batches of drugs.
These reviews of current regulatory actions helped to
reinforce commitment to understanding and meeting the
customer’s requirements. Janssen Pharmaceutica cannot
a￿ ord this type of business impact.
The next category of measurement is cost. Key meas-
urements in this category are as follows:
. cost of quality organization as a percentage of sales;
. productivity, tests per analyst;
. headcount;
. cost of quality as a percentage of cost of goods sold;
. cost of lot disposition.
Because 45% of the headcount is laboratory related, the
cost of the quality organization is for the most part a
laboratory issue. As previously mentioned, new equip-
ment was purchased at a cost of over $1MM. The
depreciation on this investment will remain for several
years. System improvements, e.g. LIMS, data manage-
ment, Y2K assurances, etc. are all cost drivers for the
laboratory and quality organization. It is clear from a
management perspective that Janssen must invest; how-
ever, these investments must be well planned and ba-
lanced with the business growth. As previously
mentioned, Janssen is somewhat unique with headquar-
ters in Belgium, production site in Puerto Rico and
administrative o￿ ces in New Jersey. Methods are devel-
oped in Belgium, evaluated and transferred to New
Jersey where stability and support process start-up are
performed, and then transferred to Puerto Rico for
production start-up. In the past, methods were developed
with a European perspective and then modi® ed for those
products being sold in the US. As a competitive global
company, this approach can no longer be a￿ orded;
methods must now be developed with a global mindset.
Once production starts up and forecasts are validated,
the Titusville laboratories move into a method improve-
ment mode, looking for e￿ ciencies and cost savings.
Recently, a robotics program for high-volume products
was embarked upon. The ® rst experience took over nine
months and was almost given up. The Titusville group
working with the Puerto Rico Labs and Zymark devel-
oped the robotic methods for dissolution, assay and
content uniformity of one of the high-volume products.
The SOPS were developed and approved, methods were
transferred, dossiers were prepared and approved, and
training completed. At last, implementation was immi-
nent. The robot was fondly named `R2D2’. Within 2
weeks of implementation, low assay was experienced in
one of the samples. The sample was redone and the root
cause of the problem could not be identi® ed. The labora-
tory analysts and supervisor of this, the ® rst robotic
approach, were stunned. Would the robot be unreliable?
Would all the work put into this programme be for
nothing? The analysts, Raul Homs and Lillian Vazquez,
would not give up. They scratched their heads, called
Zymark, the supplier, and still no root cause was deter-
mined. These analysts were persistent. They borrowed
the company video camera and set it up to run for 24 h.
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change the tapes.
The next morning, the tapes revealed the problem. The
tablet was vacuumed up and plugged the canula. This
was the root cause, and it was caught and documented on
tape! The problem could then be explained, the batch
dispositioned, and, by raising the canula, a recurrence
prevented. The robotics programme was again back on
track. The implementation of four additional product-
focused robotics programmes within the next nine
months is planned.
Robotics savings on cost:
. four analysts;
. reduced cycle time by 48 h;
. improved compliance.
The ® rst robotics experience saved the company well in
excess of $300 000 annually. Additionally, the headcount
saved meant that sta￿ were able to be reassigned to
bring in outside testing at a cost avoidance of $500000
annually. Next could be the installation of an LIMS
system, looking at NEAR IR programs and others that
will facilitate laboratory e￿ ciencies so that productivity
can be increased and cost decreased.
Lastly, the key customer measurement is time. It is
necessary to be vigilant in challenging laboratory cycle
time. Here is where programmes established can a￿ ect
headcount, inventories and complianceÐ all impacting
cost and time-to-market. Key measures for time are:
. cycle time for raw material testing: sample-in to
sample disposition;
. cycle time for bulk product testing: sample-in to
sample disposition;
. cycle time for ® nished goods testing: sample-in to
sample disposition:
. cycle time for documentation review and product
disposition.
Lower cycle time means less inventory, less inventory
means less carrying costs and improved customer satisfac-
tion; the product is available when the customer wants
itÐ no backorder. By focusing on the metrics and report-
ing out on a quarterly basis, issues are brought forward
and successes are rewarded.
As previously mentioned, Janssen compete for best prac-
tice and benchmark position internally and externally.
Internally, Janssen `peel the onion’ on the data to under-
stand who is doing best and why and then implement
these best practices across all of the sites. Similar data are
compared with competitors via a third party. This helps
to understand how Janssen are doing in relation to the
rest of the industry, and prompts competitiveness and
innovation to improve.
The Credo advised that the second order of priority is the
employee, the greatest resource and competitive weapon.
Janssen’s Credo:
. We are responsible to our employees, the men and
women who work with us throughout the world.
Everyone must be considered as an individual.
. We must respect their dignity and recognize their
merit.
. They must have a sense of security in their jobs.
. Compensation must be fair and adequate, and
working conditions clean, orderly and safe.
. We must be mindful of ways to help our employees
ful® l their family responsibilities.
. Employees must feel free to make suggestions and
complaints.
. There must be equal opportunity for employment,
development and advancement for those quali® ed.
. We must provide competent management; their
actions must be just and ethical.
Janssen’s goal is to attract, develop, promote and retain
the best employees. From a laboratory perspective and in
this current job market, this is not an easy task. Several
approaches are being experimented with in this area.
Human resource excellence:
. college recruiting programme;
. technical and managerial ladder;
. reward systems;
. rotational opportunities;
. training;
. facilities/instrumentation
While salary is an important part of hiring and retaining
employees, there are other areas of importance. People
want to be developed, learn what is the latest in instru-
mentation, become a business partner and understand
how their contributions impact the business. At Janssen,
the need to hire experienced lab personnel who can `hit
the ground running’ is balanced with entry-level posi-
tions. A college recruitment programme is being em-
barked upon for all levels of college graduate. Alliances
with Drew University, Seton Hall and Temple are being
cultivated. Janssen are working with Seton Hall to bring
a Master’s Degree programme to one of the J&J facilities
in NJ so that personnel can continue their education with
minimal travel and expense. A similar programme is also
being pursued with Temple focused on QA/RA Master’s
Degree curricula. A dual ladder programme is being
prepared. In the laboratory, if one chose to stay at the
bench and continue to develop and contribute, there was
no place to go. It was ® nally realized that not all
scientists are managers! This needs to be recognized, as
well as the fact that a key chemist or scientist contributes
equally as much as a senior manger. As a result, a
technical ladder is being developed that would provide
® nancial and title recognition for those who do not wish
to enter the managerial ranks, but contribute on a
scienti® c basis.
Reward systems are in place. Often in the past, new
product teams would be rewarded when a new product
was approved. Recognition for the contribution of the
labs was omitted. They are now integrated into the team
structure and are recognized along with the rest of the
team for their commitment and contributions. In addi-
tion, when major method breakthroughs occur, problem
solving or method improvements are brought forward, an
additional recognition is o￿ ered which ranges from 1 to
5% of salary.
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rotation to other J&J companies within the US, in Puerto
Rico or abroad is o￿ ered. This provides growth scienti-
® cally and culturally making the employee more valu-
able to the Corporation as his or her span of in¯ uence is
usually expanded during and after this experience.
Human Resource excellence cannot be achieved without
training. All employees want to improve themselves and
their ability to contribute. At Janssen, Hank Avallone,
the Executive Director of Compliance, worked with
several sister company contributors to develop the
GMP 13 Compliance Manual. This manual focuses on
the compliance requirements for the Janssen Companies.
Laboratory controls, laboratory management, stability,
deviations, etc. make up a signi® cant part of the manual.
Hank also arranges an annual meeting with the FDA
both in the US and in Puerto Rico. This gives the
analysts the opportunity to interface with the FDA,
hear the current thinking of customers, and ask questions
that would not be possible during a speci® c inspection.
Facilities and instrumentation are also key to attracting
and retaining a strong employee workforce. A pleasant,
safe work area, with basic needs, child care, on-site
exercise facility, cleaners, bank, etc. are all part of the
Janssen e￿ ort to hire and retain the best employees.
Janssen’s Credo:
. We are responsible to the communities in which we
live and work, and to the world community as well.
. We must be good citizensÐ support good works and
charities, and bear our fair share of taxes.
. We must encourage civic improvements and better
health and education.
. We must maintain in good order the property we
are privileged to use, protecting the environment
and natural resources.
After customer and employee needs are ful® lled, the
Credo requires focus on the community. We are encour-
aged to respect business neighbours and support the
needs of the communities in which we live and work.
Again, from a laboratory perspective, it is necessary that
all OSHA, EPA and DEA, etc. requirements are met.
Laboratory solvents, waste, etc. must be stored properly
and discarded according to local and federal laws. As
with compliance, internal Janssen audits as well as cor-
porate audits are performed in these areas to ensure
compliance with the regulations. Overall safety, audit,
OSHA and EPA inspection results are reviewed with the
Management Board at least annually.
Employees are also encouraged to support community
agencies, e.g. United Way, Walk for the Cure, Blood
Drives, Road Cleanup, Habitat, etc.
Janssen’s Credo:
. Our ® nal responsibility is to our stockholders.
. Business must make a sound pro® t.
. We must experiment with new ideas.
. Research must be carried on, innovative programs
developed and mistakes paid for.
. New equipment must be purchased, new facilities
provided and new products launched.
. Reserves must be created to provide for adverse
times.
. When we operate according to these principles, the
stockholders should realize a fair return.
Lastly, if all the above priorities are deliveredÐ customer,
employees and communityÐ the return on investment for
the stockholders will be favourable and more investment
for new products, facilities and overall business growth
will be encouraged.
Conclusion
Finally, management needs to be mentioned. Too often
the laboratory is neglected; its personnel and contribu-
tions to the business and bottom line. Attention is not
usually paid until there is a negative event. To become
and stay leaders in industry, it is essential to pay atten-
tion.
Management responsibility:
. authorization of resources;
. establishment of timeframes;
. correction of objectionable conditions.
Management are responsible for authorizing resources,
establishing timeframes and addressing objectionable
conditions. These issues cannot be delegated or ignored.
The laboratory plays a key role in:
. product development;
. time to market;
. product quality assurance;
. product cost;
. customer satisfaction.
Everyone has the responsibility to pay attention and
challenge how things can be done faster, better, cheaper,
safer. The laboratory is no exception and can only
succeed with the support of the management.
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